Ondas stock jumps in premarket after $1 billion ONDS offering closes — what to watch next

Ondas stock jumps in premarket after $1 billion ONDS offering closes — what to watch next

NEW YORK, January 14, 2026, 08:29 (EST) — Premarket update

  • ONDS shares climbed roughly 5% in premarket action following the closure of a $1 billion stock-and-warrant offering
  • Company expects about $959 million in net proceeds, with upside possible if warrants are exercised
  • Investors are eyeing a CEO conference appearance today and an investor day on Jan. 16 for clues on spending plans

Ondas Holdings Inc shares jumped 5.4% to $13.89 in premarket Wednesday following news that the company has completed a roughly $1 billion share-and-warrant sale to an institutional investor.

The deal is significant because it leaves a small-cap defense and industrial tech supplier with an unusually large cash reserve, just as investors demand clearer routes from product hype to actual revenue and cash flow.

The announcement reignites the immediate question for ONDS: how quickly Ondas puts the proceeds to work, and if that investment drives enough growth to counterbalance the dilution from issuing new securities.

Ondas reported selling 19 million common shares along with pre-funded warrants that allow the purchase of up to 41.79 million shares. Each “common stock equivalent” comes bundled with warrants granting the option to buy two additional shares. The company expects net proceeds around $959.2 million. The warrants have a $28 exercise price and expire in seven years. (Ondas Holdings Inc.)

A registered direct offering involves selling securities directly to an investor, with those securities already registered with the SEC, bypassing a wide public marketing effort. Pre-funded warrants function almost like shares: the buyer settles most of the cost upfront and later pays a small fee to convert them.

Ondas said it will channel the proceeds into corporate development and strategic growth, covering acquisitions, joint ventures, and investments. That hands traders fresh catalysts to factor in—and new opportunities for management to stumble.

Stifel’s Jonathan Siegmann bumped his price target for Ondas to $17 from $13, maintaining a “Buy” rating, per a GuruFocus report. (GuruFocus)

Earlier this month, Chairman and CEO Eric Brock described Ondas as more than just a drone manufacturer, stating, “today, we operate as a scaled, global defense and security technology platform.” (Ondas Holdings Inc.)

That said, the structure works against shareholders too. The share count will climb, the looming warrant stack shadows the stock, and the potential $3.4 billion from warrant exercises hinges on ONDS staying well above $28 long enough to tempt conversions.

Execution risk is another concern for investors. Acquisitions and joint ventures can quickly drain cash, and updates often come in bursts—fueling volatility but not always inspiring confidence.

Traders are set to tune in for new insights when Brock takes part in a fireside chat at the Needham Growth Conference, scheduled for 8:45 a.m. ET on Wednesday, according to the company. (Ondas Holdings Inc.)

Ondas is set to hold its virtual investor day on Jan. 16 at 10:00 a.m. ET. The company will outline its 2026 business plan and financial outlook during the session. (Ondas Holdings Inc.)

Stock Market Today

  • Novavax jumps 11.9% on Cantor Fitzgerald upgrade; eyes on 2025 sales and Matrix-M potential
    January 14, 2026, 10:14 AM EST. Novavax NVAX jumped 11.9% in the last session, closing at $8.67 on stronger-than-average volume. The move followed reports that Cantor Fitzgerald reiterated an Overweight rating with a $18 target, more than double the current price. Cantor sees 2025 sales improving as Nuvaxovid gains momentum under Sanofi's commercial leadership, and views Novavax's Matrix-M vaccine platform as a long-term asset. The stock also climbed after a four-week run of about 17.8%. Analysts expect a quarterly loss of $0.66 per share (EPS = earnings per share) and revenue of $78.41 million, down 11.2% year over year. A higher or lower revision in earnings estimates often moves prices in the near term, and Novavax currently has a Zacks Rank #3 (Hold). Ocugen, in the same space, rose 7.3%.
Bank of America Q4 2025 earnings beat: BAC profit rises as trading and net interest income jump
Previous Story

Bank of America Q4 2025 earnings beat: BAC profit rises as trading and net interest income jump

Wells Fargo stock slides before the bell as 2026 net interest income view disappoints
Next Story

Wells Fargo stock slides before the bell as 2026 net interest income view disappoints

Go toTop